CA74764Y2050
© Globe Newswire
28.11.2025
QNTM
LISTED
NASDAQ
REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
News Preview
TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 has aired Part 2 of a three-part series about Quantum Biopharma and the company’s allegations of stock market manipulati...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.11.2025
QNTM
LISTED
NASDAQ
Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
News Preview
TORONTO, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 has aired Part 2 of a three-part series about Quantum Biopharma and the company’s allegations of stock market manipulati...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.11.2025
QNTM
LISTED
NASDAQ
Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5
News Preview
TORONTO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 will air, starting today, a three-part series about Quantum Biopharma and the company’s allegations of stock market mani...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
07.11.2025
QNTM
LISTED
NASDAQ
Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern’ Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio
News Preview
Quarter Shows Company’s Continued Strong Financial Position and Momentum with its MS Clinical Trials and unbuzzd™ Recreational Beverage and Alcohol Metabolizer Quarter Shows Company’s Continued Strong Financial Position and Momentum with its MS Clinical Trials and unbuzzd™ Recreational Beverage and Alcohol Metabolizer...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
31.10.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Ltd. Provides Corporate Update
News Preview
TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K9A) (“Quantum” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that pursuant to the entry into its previously announced at the market offering agre...
Themefolio
Profiler
Peergroup
© Newsfile
30.10.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Ltd. Announces Corporate Updates
News Preview
Toronto, Ontario--(Newsfile Corp. - October 29, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disor...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend
News Preview
TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and al...
Themefolio
Profiler
Peergroup
© BusinessWire
10.10.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM
News Preview
The DJS Law Group announces that it is investigating claims on behalf of investors of Quantum BioPharma Ltd. (“Quantum BioPharma” or “the Company”) (NASDAQ: QNTM) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertin...
Themefolio
Profiler
Peergroup
© BusinessWire
10.10.2025
QNTM
LISTED
NASDAQ
KILL Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM
News Preview
DJS Law Group requests that their press release NewsItemId: 20251009668999 issued October 9, 2025 “Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM” be killed.
The release was issued in error by DJS Law Group
A replacement release will not be issued....
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2025
QNTM
LISTED
NASDAQ
QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quantum BioPharma Ltd. (“Quantum BioPharma” or “the Company”) (NASDAQ: QNTM) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2025
QNTM
LISTED
NASDAQ
KILL QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm requests that their press release NewsItemId: 20251009948258 issued Oct. 9, 2025 “QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm” be killed.
The release was issued in error by The Schall Law Firm.
A replacement release will not be issued....
Themefolio
Profiler
Peergroup
© Globe Newswire
08.10.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock
News Preview
Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
03.10.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case
News Preview
TORONTO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced today that its Board of Directors has established October 27, 2025 as the record date f...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.09.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders
News Preview
TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and...
Themefolio
Profiler
Peergroup
© Newsfile
27.09.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Announces Corporate Updates
News Preview
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic dis...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025
News Preview
TORONTO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse dis...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
QNTM
LISTED
NASDAQ
Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance
News Preview
TORONTO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and a...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.09.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT
News Preview
TORONTO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and a...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2025
QNTM
LISTED
NASDAQ
Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target
News Preview
This was unpaid research with no consideration given This was unpaid research with no consideration given...
Themefolio
Profiler
Peergroup
© Newsfile
12.08.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Announces Update to Previously Announced Private Placement
News Preview
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that further to its press release dated June 27, 2025, the Company will be se...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.08.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
News Preview
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has sign...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients
News Preview
Ongoing Joint Clinical Study Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302 Ongoing Joint Clinical Study Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2025
QNTM
LISTED
NASDAQ
Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of
News Preview
Unprecedented Quarter Shows Company’s Strong Financial Position and Continued Momentum with its Multiple Sclerosis Clinical Trials and unbuzzdTM Recreational Beverage and Alcohol Metabolizer Unprecedented Quarter Shows Company’s Strong Financial Position and Continued Momentum with its Multiple Sclerosis Clinical Trials and unbuzzdTM Recreational B...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.08.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing
News Preview
TORONTO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that on July 31, 2025 it filed a memorandum of law in opposition to defendants’ C...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO
News Preview
This Offering Will Not Dilute Quantum BioPharma Shareholders This Offering Will Not Dilute Quantum BioPharma Shareholders...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.06.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Announces Private Placement
News Preview
TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it is completing a non-brokered private placement of class A multiple...
Themefolio
Profiler
Peergroup
© Newsfile
18.06.2025
QNTM
LISTED
NASDAQ
Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress
News Preview
Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies, today released its analysis of Quantum BioPharma Ltd.'s (NASDAQ: QNTM) continued progress across its innovative pipeline of treatments for brain disorders and alcohol health.A link to the report is availa...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.06.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
News Preview
TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce its intention to declare a special dividend consisting of Contingent Value...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
News Preview
Dr. Raza Bokhari, Company’s Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years Dr. Raza Bokhari, Company’s Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets
News Preview
TORONTO, May 21, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has selected BitGo Trust Company (“BitGo”) as one of its partners to secur...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
News Preview
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that dosing of drug has completed in 90-day oral toxicity and toxicokinetic studie...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.05.2025
QNTM
LISTED
NASDAQ
Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
News Preview
To assist enquiries a copy of the amended complaint can be viewed by clicking the following link:Quantum Amended Court Claim...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.04.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time
News Preview
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time...
Themefolio
Profiler
Peergroup
© Newsfile
19.04.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Corporate Update
News Preview
Toronto, Ontario--(Newsfile Corp. - April 18, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorde...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.04.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
News Preview
QUANTUM BIOPHARMA LICENSEE CELLY NUTRITION LAUNCHES UNBUZZD IN PUERTO RICO...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.04.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis
News Preview
TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that on March 31, 2025 it has entered into a joint clinical study with Massachusetts Ge...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.03.2025
QNTM
LISTED
NASDAQ
Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms
News Preview
TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”) is pleased to announce that it has closed the final tranche (“Final Tranche”) of the offering announced on December 5, 2024 (the “December 5 NR”) as amended on January 20, 2025, and based on the better t...
Themefolio
Profiler
Peergroup
© Newsfile
31.03.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Provides Corporate Update
News Preview
Toronto, Ontario--(Newsfile Corp. - March 30, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has renewed the services of King Tide Media LLC based at 806E Windwar...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.03.2025
QNTM
LISTED
NASDAQ
Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
News Preview
Completion of unbuzzd™ Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company’s Pipeline of Products and Assets Completion of unbuzzd™ Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company’s Pipeline of Products and Assets...
Themefolio
Profiler
Peergroup
© Newsfile
17.03.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Unaware of Any Material Change
News Preview
Toronto, Ontario--(Newsfile Corp. - March 17, 2025) - At the request of the Canadian Investment Regulatory Organization, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (the "Company") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increas...
Themefolio
Profiler
Peergroup
© Newsfile
08.03.2025
QNTM
LISTED
NASDAQ
Quantum BioPharma Provides Corporate Update
News Preview
Toronto, Ontario--(Newsfile Corp. - March 7, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates.Warrant CancellationEffective today, the Company has canc...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.02.2025
QNTM
LISTED
NASDAQ
Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial
News Preview
Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impair...
Themefolio
Profiler
Peergroup
© Newsfile
21.10.2024
QNTM
LISTED
NASDAQ
Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
News Preview
Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholdersToronto, Ontario--(Newsfile Corp. - October 21, 2024) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CS...
Themefolio
Profiler
Peergroup
© Newsfile
07.10.2024
QNTM
LISTED
NASDAQ
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America
News Preview
Toronto, Ontario--(Newsfile Corp. - October 7, 2024) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma") provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu" or the "Company"), and its launching of unbuzzd™, an innovative beverage product that is scientifically formulated fr...
Themefolio
Profiler
Peergroup
© Newsfile
14.09.2024
QNTM
LISTED
NASDAQ
Quantum BioPharma Closes Private Placement Offering
News Preview
Toronto, Ontario--(Newsfile Corp. - September 13, 2024) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K9) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that, further to its press release dated September 6, 2024 (the "September...
Themefolio
Profiler
Peergroup
© Newsfile
15.08.2024
QNTM
LISTED
NASDAQ
FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol "QNTM"
News Preview
Toronto, Ontario--(Newsfile Corp. - August 15, 2024) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) ("Quantum BioPharma" or the "Company"), formerly FSD Pharma Inc., a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that, further to its press release dated August 9,...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
